Literature DB >> 31875301

A case of Cerebrotendinous Xanthomatosis with spinal cord involvement and without tendon xanthomas: identification of a new mutation of the CYP27A1 gene.

Monica Gelzo1,2, Maria Donata Di Taranto1,2, Alvino Bisecco3, Alessandra D'Amico4, Rocco Capuano3, Carola Giacobbe2, Mafalda Caputo1, Mario Cirillo3, Gioacchino Tedeschi3, Giuliana Fortunato1,2, Gaetano Corso5.   

Abstract

Cerebrotendinous Xanthomatosis (CTX) is an autosomal recessive defect of the alternative pathway of bile acid biosynthesis, due to the deficiency of mitochondrial cytochrome P450 sterol 27-hydroxylase enzyme encoded by CYP27A1. The deficit of sterol 27-hydroxylase raises cholestanol in plasma and tissues of affected patients. Although there is a marked variability of signs, symptoms, severity and age of onset, the main clinical manifestations of CTX include chronic diarrhea, bilateral cataract, tendon xanthomas and neurological dysfunction. Herein, we report the clinical, biochemical and molecular characterization of a Caucasian female affected by CTX diagnosed at 28 years. The patient's clinical history revealed neurological and behavioral manifestations already at fifth year of life, following by bilateral cataract and chronic diarrhea without xanthomas. At diagnosis, an involvement of the cervical spinal cord was also observed on MRI. Sterols profile analysis in plasma and red blood cell membranes showed very high cholestanol levels. CYP27A1 sequencing revealed a new variant (e.g., c.850_854delinsCTC) at homozygous status. The follow-up after 5 months of chenodeoxycholic acid treatment showed a decrease of plasma cholestanol of 64%. After 1 year, the patient showed normalization of bowel function, reduction of risk of falls, improvement of cognitive function although brain and spine MRI and other instrumental examinations remained unchanged. This case highlights the variability of the CTX phenotype that makes it difficult to reach an early diagnosis. Biochemical and/or molecular screening of CTX should be taken into account to early start the pharmacological treatment limiting neurological damages.

Entities:  

Keywords:  Bile acid biosynthesis disorder; CYP27A1; Cerebrotendinous Xanthomatosis; Neurological dysfunction; Sterol 27-hydroxylase

Year:  2019        PMID: 31875301     DOI: 10.1007/s13760-019-01267-4

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  2 in total

1.  Spinal cerebrotendinous xanthomatosis: A case report and literature review.

Authors:  Isis Atallah; Diego San Millán; Wicki Benoît; Belinda Campos-Xavier; Andrea Superti-Furga; Christel Tran
Journal:  Mol Genet Metab Rep       Date:  2021-02-03

Review 2.  The clinical and imaging features of cerebrotendinous xanthomatosis: A case report and review of the literature.

Authors:  Chi Ma; Yan-De Ren; Jia-Chen Wang; Cheng-Jian Wang; Ji-Ping Zhao; Tong Zhou; Hua-Wei Su
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.